Document is current
Any future updates will be listed below
-
Authors
Nakahara, Takeshi
Murota, Hiroyuki
Matsukawa, Miyuki
Takeda, Hiroe
Zhang, Yilong
Kondo, Tomohiro https://orcid.org/0009-0002-7275-359X
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical
- License Information
-
More Information
Article History
Received: 29 July 2024
Accepted: 20 September 2024
First Online: 4 October 2024
Declarations
:
: Takeshi Nakahara has received consulting fees and/or speaker honoraria from Mitsubishi Tanabe Pharma Corporation, Taiho Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd., Maruho Co., Ltd., Sanofi K.K., AbbVie GK, Eli Lilly Japan K.K., Sun Pharma Japan Ltd. and Otsuka Pharmaceutical Co., Ltd. Hiroyuki Murota has received consulting fees and/or speaker honoraria from Maruho Co., Ltd., Sanofi K.K., Pfizer Japan Inc., Torii Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., AbbVie GK, and Otsuka Pharmaceutical Co., Ltd. Miyuki Matsukawa, Hiroe Takeda, Yilong Zhang, and Tomohiro Kondo are employees of Otsuka Pharmaceutical Co., Ltd. This study was conducted by authors who are employees of Otsuka Pharmaceutical, but the results were objectively evaluated using legitimate methods.
: The two phase 3 studies used for this analysis were conducted in accordance with the Declaration of Helsinki and local regulations. The protocols for these two studies were approved by the authorities and the ethics committees of the respective institutions, and signed informed consent was obtained from all patients. Informed consent for this analysis was not required given the use of anonymized patient-level data from previously published articles.
